PropertyValue
?:abstract
  • The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
?:creator
?:doi
  • 10.1007/s00415-020-09944-8
?:doi
?:journal
  • J_Neurol
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/7a72cfc8a76468d0e59adc456b53fedea386ab84.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7268971.xml.json
?:pmcid
?:pmid
?:pmid
  • 32494856.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • COVID-19 in teriflunomide-treated patients with multiple sclerosis
?:type
?:year
  • 2020-06-03

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/cdp49bk5>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/cdp49bk5>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all